{
    "nct_id": "NCT05475210",
    "official_title": "Phase I, Open-Label Study of the Safety and Dosimetry of a 3-Dose Regimen of Escalating Doses of 177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors",
    "inclusion_criteria": "Ability to understand and willing to sign a written informed consent document\n\nAged 18 years or older\n\nHistologically proven or cytologically confirmed, inoperable, GEP-NETs\n\nNeuroendocrine tumors (NETs) of grade 1, 2 and 3 according to World Health Organization (WHO) 2017 classification\n\nMeasurable disease as defined by Response Criteria in Solid Tumors (RECIST) version 1.1\n\nOverexpression of somatostatin receptors of the target lesions in 68Ga-DOTA-TATE positron emission tomography (PET)/computed tomography (CT) with SUV of lesions greater than normal liver in at least 1 lesion\n\nA Cockcroft Gault calculated creatinine clearance > 60 mL/min\n\nKarnofsky performance status scale ≥ 70%\n\nWomen of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation, including follow-up (7 months after the last dose of study drug for women and 4 months for men).\n\nPrevious local therapy (e.g., chemoembolization or bland embolization) is allowed if completed >4 weeks prior to study entry.\n\nPrevious surgery no less than 6 weeks prior to study entry.\n\nEither no prior treatment with 177Lu-DOTA-TATE or at least 12 months progression-free survival (PFS) after prior treatment with 177Lu-DOTA-TATE\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "Women who are pregnant or breastfeeding\n\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to 177Lu-DOTA-EB-TATE as assessed from medical records\n\nPrevious treatment with more than 4 cycles of 177Lu-DOTA-TATE\n\nParticipant has had prior chemotherapy, targeted cancer therapy, immunotherapy, or treatment with an investigational anticancer agent within 4 weeks or 4 half-lives whichever is longer, before the first administration of study drug.\n\nParticipant has not fully recovered from major surgery or significant traumatic injury prior the first dose of study drug or expects to have major surgery during the study period or within 3 months after the last dose of study drug.\n\nLife expectancy < 6 months as assessed by the treating physician\n\n> 80% liver involvement by tumor\n\n> 25% bone marrow involvement by tumor\n\nPoorly differentiated neuroendocrine neoplasms, such as poorly differentiated neuroendocrine carcinoma, small- and large-cell neuroendocrine carcinoma; mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN); Grade 3 neuroendocrine carcinomas (NEC)\n\nPresence of somatostatin receptor negative lesions if they cannot be addressed with loco-regional therapies prior to the treatment start\n\nDeteriorated renal function, as indicated by a serum creatinine clearance > 1.7 mg/dL\n\nDeteriorated bone marrow function\n\nDeteriorated liver function\n\nToxicities from prior therapies that have not resolved to grade 1 or grade 0\n\nActive and clinically significant bacterial, fungal, or viral infection, including hepatitis B (HBV), hepatitis C (HBC), know human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS)-related illness\n\nKnown brain metastases and/or carcinomatous meningitis, unless these metastases have been treated and stabilized\n\nUncontrolled diabetes mellitus as defined by a HbA1c >9%\n\nImpossibility to interrupt short-acting octreotide for 24 h before and 24 h after the administration of 177Lu-DOTA-EB-TATE; impossibility to have an interval of ≥4 weeks between octreotide and 177Lu-DOTA-EB-TATE\n\nThe use of somatostatin and its analogues within 4 months of a planned 177Lu-DOTA-EB-TATE treatment\n\nUncontrolled, intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n\nPrior external beam radiation therapy involving >25% of the bone marrow\n\nUnmanageable urinary incontinence rendering the administration of 177Lu-DOTA-EB-TATE unsafe\n\nOther known co-existing malignancies except non-melanoma skin cancer and carcinoma in situ of the uterine cervix, unless definitively treated and with no evidence of recurrence",
    "miscellaneous_criteria": ""
}